The following members were the largest shareholders in terms of voting rights according to the shareholders register as of
Fjärde AP-fonden: Jannis Kitsakis
The chairman of the Nomination Committee is
In total, the Nomination Committee represents approx. 27% of the total number of shares and 44% of the votes in the company. All representatives except
The Committee's assignment is to present proposals to the AGM regarding; election of the Chairman of the AGM, election of Chairman and other members of the Board, election of Auditors as well as remuneration to the Board´s members and auditor fees.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to the Chairman of the Nomination Committee: pea@pealaw.se
or by phone +46 (0)70 537 98 92.
For further information, please contact:
Tel. +46 (0) 70 861 88 42
Email: marie-louise.alamaa@ibtherapeutics.com
Publication
The information was submitted for publication, through the agency of the contact person set out above, at 16.15 CET on
About
IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Attachment
- PR 20211029 Nominating Committee ENG
© OMX, source